Text Size

Improving Management of Patients at High Risk for Osteoporotic Fractures

This study has been completed.
Sponsor:
Information provided by:
Merck
ClinicalTrials.gov Identifier:
NCT00139438
First received: August 29, 2005
Last updated: October 25, 2009
Last verified: October 2009
History of Changes
  Purpose

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.


Condition Intervention
Osteoporosis
 Behavioral: Disease Management Assessment

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Official Title: Improving Management of Patients at High Risk for Osteoporotic Fractures

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Merck:

Primary Outcome Measures:
  • A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.

Secondary Outcome Measures:
  • BMD testing, osteoporosis medication prescriptions, fracture

Estimated Enrollment: 4266
Study Start Date: September 2004
Primary Completion Date: June 2005 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   45 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).

Exclusion Criteria:

  • Individuals who are not members of Horizon Blue Cross Blue Shield of New Jersey and who otherwise do not meet the inclusion criteria.
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00139438

Sponsors and Collaborators
Merck
Investigators
Principal Investigator: Daniel H. Solomon, M.D., M.P.H. Brigham and Woman's Hospital
  More Information

No publications provided

Responsible Party: Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
ClinicalTrials.gov Identifier: NCT00139438     History of Changes
Other Study ID Numbers: 2005_049, 038
Study First Received: August 29, 2005
Last Updated: October 25, 2009
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Osteoporosis
Osteoporotic Fractures
Bone Diseases, Metabolic
Bone Diseases
 Musculoskeletal Diseases
Fractures, Bone
Wounds and Injuries

ClinicalTrials.gov processed this record on May 19, 2013